Rakha, E. A., Miligy, I. M., Quinn, C. M., Provenzano, E., Shaaban, A. M., Marchiò, C., . . . Lee, A. H. S. (2021). Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases. Br J Cancer.
Chicago Style CitationRakha, Emad A., et al. "Retrospective Observational Study of HER2 Immunohistochemistry in Borderline Breast Cancer Patients undergoing Neoadjuvant Therapy, With an Emphasis On Group 2 (HER2/CEP17 Ratio ≥2.0, HER2 Copy Number <4.0 Signals/cell) Cases." Br J Cancer 2021.
MLA CitationRakha, Emad A., et al. "Retrospective Observational Study of HER2 Immunohistochemistry in Borderline Breast Cancer Patients undergoing Neoadjuvant Therapy, With an Emphasis On Group 2 (HER2/CEP17 Ratio ≥2.0, HER2 Copy Number <4.0 Signals/cell) Cases." Br J Cancer 2021.